MedTrace Logo

High Dose BAYA1040_Nifedipine: a Dose-comparative Study

NCT01287260 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2014-01-29

No results posted yet for this study

Summary

This is a clinical study evaluating the superiority in efficacy and assess safety and tolerability of BAYA1040\_Nifedipine 80 mg/day (40 mg twice daily) compared with BAYA1040\_Nifedipine 40 mg/day (40 mg once daily) in patients with essential hypertension who are not at target blood pressure by BAYA1040\_Nifedipine 40 mg once daily treatment.

Conditions

Interventions

DRUG

Nifedipine (Adalat, BAYA1040)

BAYA1040\_Nifedipine 40mg twice daily (BID)

DRUG

Nifedipine (Adalat, BAYA1040)

BAYA1040\_Nifedipine 40mg once daily (OD)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01287260 on ClinicalTrials.gov